We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $1.93B
1-Year Est. Return 134.74%
This Fund
S&P 500
This Quarter Est. Return
+0.93%
1 Year Est. Return
+134.74%
3 Year Est. Return
+450.5%
5 Year Est. Return
+913.18%
10 Year Est. Return
–
AUM
$1.11B
AUM Growth
+$17.7M
Cap. Flow
+$78.3M
Cap. Flow %
7.08%
Top 10 Hldgs %
56.11%
Holding
90
New
21
Increased
23
Reduced
6
Closed
19

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$17.7M
2
PFE icon
Pfizer
PFE
+$15.7M
3
UTHR icon
United Therapeutics
UTHR
+$15.6M
4
BMY icon
Bristol-Myers Squibb
BMY
+$14.3M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$12.6M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$22.8M
2
NVO
Novo Nordisk
NVO
+$16.5M
3
HRTX icon
Heron Therapeutics
HRTX
+$9.45M
4
INCY icon
Incyte
INCY
+$5.91M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$4.16M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
2 Miscellaneous 6.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AUTL
76
Autolus Therapeutics
AUTL
$540M
– –
-65,780
Closed -$1.06M
BMY icon
77
CALL
Bristol-Myers Squibb
BMY
$132B
– –
-100,000
Closed -$4.53M
INCY icon
78
Incyte
INCY
$25.5B
– –
-69,612
Closed -$5.91M
NVO
79
Novo Nordisk
NVO
$197B
– –
-647,394
Closed -$16.5M
QURE icon
80
CALL
uniQure
QURE
$3.19B
– –
-50,000
Closed -$3.91M
ITCI
81
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-175,000
Closed -$2.27M
ITCI
82
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-125,955
Closed -$1.64M
DCPH
83
PUT
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-100,100
Closed -$2.26M
RVLP
84
DELISTED
RVL Pharmaceuticals plc Ordinary Shares
RVLP
– –
-525,198
Closed -$2M
ACOR
85
DELISTED
Acorda Therapeutics
ACOR
– –
-1,617
Closed -$1.49M
CLVS
86
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-125,303
Closed -$1.86M
AGN
87
CALL
DELISTED
Allergan plc
AGN
– –
-50,000
Closed -$8.37M
ZGNX
88
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-50,000
Closed -$2.39M
1 2 3
4

Similar funds

GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
EK
Evensky & Katz Coral Gables, Florida $1.94B AUM 22.01% 1-Year Est. Return
CTI
Community Trust & Investment Versailles, Kentucky $1.94B AUM 29.99% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
P3I
Progeny 3 Inc Kirkland, Washington $1.94B AUM 19.13% 1-Year Est. Return
TCM
Tao Capital Management San Francisco, California $1.94B AUM 48.68% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return
SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return

Sofinnova Investments's Q3 2019 Portfolio in Review

As of Q3 2019, Sofinnova Investments held 90 positions worth $1.11B, up 1.6% from $1.09B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Sofinnova Investments deployed $78.3M of net new capital in Q3 2019, opening 21 new positions and adding to 23 existing holdings. Its largest new stake was Amgen: 92,300 shares worth $17.9M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Principia Biopharma Inc. Common Stock, an estimated $22.8M trimmed.

  • Sofinnova Investments's largest Q3 2019 buy was Amgen: 92,300 shares worth $17.9M.
  • Sofinnova Investments added most to Bristol-Myers Squibb in Q3 2019, an estimated $14.3M increase.
  • Sofinnova Investments's biggest Q3 2019 reduction was Principia Biopharma Inc. Common Stock, cutting an estimated $22.8M.
  • Sofinnova Investments fully exited Novo Nordisk in Q3 2019, selling an estimated $16.5M.
  • Sofinnova Investments's ten largest holdings make up 56% of its $1.11B portfolio in Q3 2019.
  • Sofinnova Investments opened 21 new positions and closed 19 in Q3 2019.
  • Sofinnova Investments's portfolio value rose 1.6% quarter-over-quarter to $1.11B.

Based on Sofinnova Investments's 13F filing for Q3 2019, filed 14 Nov 2019.